-       Report 
- May 2025
-  175 Pages 
- Global 
   From       €4016EUR$4,490USD£3,533GBP 
            -       Report 
- April 2025
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
            -       Clinical Trials 
- April 2025
-  80 Pages 
- Global 
   From       €1431EUR$1,600USD£1,259GBP 
      €1789EUR$2,000USD£1,574GBP 
            -       Clinical Trials 
- April 2025
-  40 Pages 
- Global 
   From       €894EUR$1,000USD£787GBP 
      €1118EUR$1,250USD£983GBP 
            -       Report 
- June 2024
-  200 Pages 
- Global 
   From       €5689EUR$6,360USD£5,004GBP 
      €7111EUR$7,950USD£6,255GBP 
             -       Report 
- February 2024
-  120 Pages 
- Asia Pacific 
   From       €3542EUR$3,960USD£3,116GBP 
      €4428EUR$4,950USD£3,895GBP 
             Liver Cirrhosis is a chronic liver disease caused by the accumulation of scar tissue in the liver. It is a progressive condition that can lead to liver failure and death. Treatment for liver cirrhosis includes lifestyle changes, medications, and in some cases, surgery. Medications used to treat liver cirrhosis include antiviral drugs, antibiotics, antifibrotic drugs, and immunosuppressants. These drugs are used to reduce inflammation, reduce the risk of infection, and slow the progression of the    disease.
The Liver and Kidney Disorders Drugs market is a rapidly growing segment of the pharmaceutical industry. This market includes drugs used to treat a variety of liver and kidney disorders, including liver cirrhosis. These drugs are used to reduce inflammation, reduce the risk of infection, and slow the progression of the disease.
Some companies in the Liver Cirrhosis Drug market include AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, and Pfizer. Show Less   Read more